Key result
Routine monitoring and dose adjustment of low-molecular-weight heparin based on anti-Xa activity is not recommended in patients with cancer due to insufficient evidence of clinical benefit.
Systematic Review
Answers are grounded in this paper and cite their sources.
LMWH dosing by weight or anti-Xa levels in cancer VTE with mild renal impairment remains unresolved; leaves open optimal strategy pending randomized data.
A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
No takes yet. Share an insight, caveat, or question.
Kreuziger et al. (2016) conducted a systematic review in Cancer-associated venous thromboembolism. Anti-Xa monitoring and dose adjustment vs. Weight-based dosing was evaluated on Bleeding and thrombotic complications. Routine monitoring and dose adjustment of low-molecular-weight heparin based on anti-Xa activity is not recommended in patients with cancer due to insufficient evidence of clinical benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: